sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Table 5

Budget impact analysis for the no-test and test (sFlt-1/PlGF) strategies.

Year	No-test strategy		Test strategy		Total cost for entire cohort (€)		Difference in costs (no-test strategy vs. test strategy; €)
		Costs (€) [19]		Costs (€)	Test/no-test strategy	No-test strategy
1	4867	53,173,304	1217	12,874,728	66,048,032	66,469,362	–421,330
2	3484	38,063,651	2600	27,505,581	63,351,915	64,221,605	–869,690
3	2434	26,592,115	3650	38,613,604	60,870,237	62,049,860	–1,179,623
4	1084	11,842,996	5000	52,895,349	58,390,277	59,951,556	–1,561,278
5	0	—	6084	64,363,060	56,088,688	57,924,209	–1,835,520
Total within 5 years	11,869	129,672,066	18,551	196,252,323	304,749,152	310,616,592	–5,867,441

PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.